[go: up one dir, main page]

CR20120436A - ANTI-ANGIOGENESIS FOR THE TREATMENT OF OVARIAN CANCER - Google Patents

ANTI-ANGIOGENESIS FOR THE TREATMENT OF OVARIAN CANCER

Info

Publication number
CR20120436A
CR20120436A CR20120436A CR20120436A CR20120436A CR 20120436 A CR20120436 A CR 20120436A CR 20120436 A CR20120436 A CR 20120436A CR 20120436 A CR20120436 A CR 20120436A CR 20120436 A CR20120436 A CR 20120436A
Authority
CR
Costa Rica
Prior art keywords
treatment
ovarian cancer
angiogenesis
relates
cancer
Prior art date
Application number
CR20120436A
Other languages
Spanish (es)
Inventor
Jakob Dupont
Cornelia Irl
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of CR20120436A publication Critical patent/CR20120436A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere, en general, al tratamiento de enfermedades y trastornos patológicos con anticuerpos anti-VEGF. Más específicamente, la invención se relaciona con el tratamiento de pacientes humanas susceptibles o con diagnóstico de cáncer utilizando un anticuerpo anti-VEGF, preferentemente en combinación con uno o más agentes terapéuticos antitumorales para el tratamiento del cáncer ovárico.The present invention relates, in general, to the treatment of diseases and pathological disorders with anti-VEGF antibodies. More specifically, the invention relates to the treatment of susceptible human patients or those diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more antitumor therapeutic agents for the treatment of ovarian cancer.

CR20120436A 2010-02-23 2012-08-21 ANTI-ANGIOGENESIS FOR THE TREATMENT OF OVARIAN CANCER CR20120436A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US35123110P 2010-06-03 2010-06-03
US36005910P 2010-06-30 2010-06-30

Publications (1)

Publication Number Publication Date
CR20120436A true CR20120436A (en) 2012-11-26

Family

ID=47290217

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120436A CR20120436A (en) 2010-02-23 2012-08-21 ANTI-ANGIOGENESIS FOR THE TREATMENT OF OVARIAN CANCER

Country Status (2)

Country Link
CR (1) CR20120436A (en)
ZA (1) ZA201307677B (en)

Also Published As

Publication number Publication date
ZA201307677B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
CO6592072A2 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
CY1124307T1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX383886B (en) HUMAN ANTI-TROP-2 ANTIBODY THAT HAS ANTI-TUMORAL ACTIVITY IN VIVO.
EA201390506A1 (en) POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201890272A1 (en) AXL-SPECIFIC CONJUGATES ANTIBODY AND MEDICINE FOR THE TREATMENT OF CANCER
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
EA201491550A1 (en) APPLICATION OF THE BINDING PROTEIN OF NEUROTROFIN RECEPTOR P75NTR FOR THERAPEUTIC PURPOSES
CO6771416A2 (en) Bispecific dual variable domain immunoglobulins of il-1 alpha and beta and their use
MX391536B (en) COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION.
PH12015500480B1 (en) Antibody formulations and uses thereof
BR112013022234A2 (en) dodecafluorpentane emulsion as a stroke and ischemia therapy
MX2017003211A (en) ANTI-MET ANTIBODIES AND COMPOSITIONS.
MX2015008117A (en) Anti-h7cr antibodies.
EA201890598A3 (en) ANTIANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION RESISTANT CANCER OF THE PROSTATE
EA201500371A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING DOUBLE ANGIPOETHIN-2 / Dll4 BINDING AGENTS AND ANTI-VEGF AGENTS
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
EA201490180A1 (en) ANTIBODIES TO ERBB3 IN COMBINATION WITH PAKLITAXEL FOR THE TREATMENT OF GYNECOLOGICAL MALIGNANT DISEASES
CR20120076A (en) ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER PREVIOUSLY TREATED
BR112014018374A8 (en) METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH CANCER, KIT, ANTIBODY, METHOD FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITION
MX362497B (en) Methods for treatment of gastric cancer.
MX2015001695A (en) TREATMENT REGIMES.
CR20120436A (en) ANTI-ANGIOGENESIS FOR THE TREATMENT OF OVARIAN CANCER